Health Affairs Briefing Specialty Pharmaceutical Spending And Policy. Alan Weil Editor in Chief Hyatt Regency Washington October 7, 2014
|
|
- Harold Curtis
- 7 years ago
- Views:
Transcription
1 Health Affairs Briefing Specialty Pharmaceutical Spending And Policy Alan Weil Editor in Chief Hyatt Regency Washington October 7, 2014
2 Health Affairs thanks For its generous support of the October 2014 cluster of articles on Specialty Pharmaceuticals and this briefing.
3 Follow Live Tweets From The Join In The Conversation: #SpecialtyDrugs
4 Panel 1: Cost And Value
5
6 Growth In National Health Expenditures (NHE) And Gross Domestic Product (GDP), And NHE As A Share Of GDP, Martin A B et al. Health Aff 2014;33: by Project HOPE - The People-to-People Health Foundation, Inc.
7
8
9 Spending increases are related to technological change.
10 Spending increases are driven by price increases in selected categories.
11 Despite High Costs, Specialty Drugs May Offer Value For Money Comparable To That Of Traditional Drugs James D. Chambers, PhD Assistant Professor, Center for the Evaluation of Value and Risk in Health Tufts Medical Center
12 What Did We Do? FDA drug approvals ( ) Examined if costs of specialty drugs are worth the clinical benefits Compared with traditional drugs
13 How Did We Do It? Identified estimates of additional health gains (QALYs) and costs Dataset of drugs compared to preexisting standard of care Comparison of health gain, additional cost associated with drug use, and costeffectiveness
14 What Did We Find? Specialty drug use associated with Similar higher cost- costs effectiveness median inc. costs (p = 0.35) $12,238 vs. $784 (p<0.01) but specialty drugs offer larger health gains median QALY gain vs (p<0.01)
15 What Does This Mean? Specialty drugs more expensive, but offer larger benefits In many cases offer reasonable value for money Study does not address affordability
16 Health Affairs thanks For its generous support of the October 2014 cluster of articles on Specialty Pharmaceuticals and this briefing.
17 Panel 2: Policy Issues
18 The Ethics Of Fail First Design Guidelines for Step Therapy Coverage Policies Steven Pearson, MD Founder and President Institute for Clinical and Economic Review
19 Step Therapy Coverage Policies What are they? Require patients try a less expensive treatment and fail first before the insurer will cover another, more expensive option Why use step therapy? Prudent use of limited health care resources Less restrictive than non-coverage Consistent with best scientific evidence?
20 Growing Use Of Step Therapy 67% of employer-sponsored health plans using step therapy in 2013 Used often for expensive specialty pharmaceuticals Controversies over step therapy have led to a patchwork of varying legislative restrictions across the country
21 Ethical Design Criteria Weigh short-term cost savings against long-term clinical and economic outcomes Ensure that first-step drugs are clinically appropriate for nearly all patients Give patients an excellent chance to meet clinical goals First-step failure should not cause long-term harm Clearly define failure Opting out on clinical grounds should be quick and easy Make the rationale and rules for the policy explicit and transparent Rapidly review relevant new evidence
22 Scenarios For Step Therapy Population-level evidence Drug A more effective than drug B, but drug B can be effective for many patients who fail with drug A Drugs A and B have equivalent safety and effectiveness Drugs A and B have equivalent safety and effectiveness Promising but inconclusive evidence suggests that drug B is safer, more effective, or both than drug A Drug B is safer, more effective, or both than drug A Drug B is safer, more effective, or both than drug A Heterogeneity of treatment effect Marked Limited Marked Uncertain Limited Marked Ethical burden on payers Lowest Very low Moderate Moderate High Highest
23 Policy Applications Internal guidance for payers Benchmark for accreditation bodies Framework for state or federal legislation to ensure appropriate step therapy policies
24 Existing FDA Pathways Have Potential To Ensure Early Access To, And Appropriate Use Of, Specialty Drugs Aaron Kesselheim, MD, JD Associate Professor of Medicine, Harvard Medical School Brigham and Women s Hospital, Division of Pharmacoepidemiology and Pharmacoeconomics
25 Specialty Drugs Aspects of the FDA s traditional gatekeeping role particularly relevant to review and approval of specialty drugs #1: Expedite access to lifesaving specialty drugs #2: Limit overuse
26 #1a: Expanded Access Patients with pressing clinical need seek to access investigational drugs FDA approves requests, but practical limitations remain, e.g., related to supply, difference between direct and actual cost Particularly relevant for complicated-tomanufacture and costly specialty drugs FDA: more active role? Require submission of pre-approval plan Clarify how review expedited access data
27 #1b: Expedited Approval Many pathways speed FDA approval of promising specialty drugs: fast-track, accelerated approval, priority review, breakthrough therapy (2012) : 49/82 (61%) approved fast-track drugs, 26/37 (70%) accelerated approval Challenge evidence-based prescribing FDA must better ensure timely confirmatory studies; Fines? Sunsetting? FDA must better communicate limited data
28 #2a: Limiting Overuse With Narrow Indications Overly broad approved indications invites inappropriate prescribing Examples: Target treatment ranges (Epoetin for anemia), or limited to refractory population in which drug was tested More emphasis on companion diagnostics like HercepTest Of 13 drugs explicitly approved with companion diagnostic, 12 are specialty drugs
29 #2b: Risk Evaluation And Mitigation Strategies (REMS) 2007 FDAAA allow FDA to require development of restricted prescribing plan if needed to ensure benefits outweigh identified safety risks Medication guides, certification, enhanced patient informed consent ~1/2 of 81 REMS related to specialty drugs Need broader authority to impose for specialty drugs?
30 Control Spending FDA cannot take costs into account when reviewing new drug applications Can expeditiously withdraw disproven indications for specialty drugs (see Avastin and MBC) Can also facilitate market competition by creating reliable pathway for biosimilars, since many specialty drugs are biologics
31 Conclusions Specialty drugs offer promise of substantial health benefits, require patient monitoring because of important risks, complex to manufacture, extremely costly Many existing regulatory tools can be applied to ensure efficient approval of and access to specialty drugs and promote appropriate prescribing after approval
32 Specialty Drug Coupons Lower Out-of-pocket Costs And May Improve Adherence At The Risk Of Increasing Premiums Catherine L. Starner, senior health outcomes researcher, Prime Therapeutics G. Caleb Alexander, associate professor, Department of Epidemiology, and co-director of the Center for Drug Safety and Effectiveness at Johns Hopkins Bloomberg School of Public Health Kevin Bowen, senior health outcomes researcher, Prime Therapeutics Yang Qui, data scientist, Prime Therapeutics Peter Wickersham, senior vice president for integrated care and specialty, Prime Therapeutics Patrick P. Gleason, director of health outcomes, Prime Therapeutics
33 Specialty Drug Coupons Impact At Prime Specialty Pharmacy 57% Patient pay before copay coupon After coupon Patient pay before copay coupon After coupon 3% 12% 1% Patient cost share greater than $50 Patient cost share greater than $ ,330 prescriptions with a coupon Source: Prime Therapeutics LLC
34 Cost Share Impact On Adherence Unadjusted Abandonment Rates of Specialty Drugs By 15,937 Patients Newly Initiating Or Restarting Use
35 Tools To Manage Specialty Spend Patient cost share & formulary (drug list) management Utilization management Contracting management Care / Case management Channel management Prior authorization Step therapy Quantity limit maximums per prescription fill Prime Therapeutics LLC Rebates Provider reimbursement fee schedules Patient counseling to ensure safe & effective drug use Patient services to ensure use of preferred care network and specialist Coordination of care Specialty Pharmacy network Drug purchasing discounts Optimize site of care Patient financial assistance (coupons) for preferred formulary tier drugs
36 Conclusions As patient cost shares go beyond $250 per month, more patients abandon their drug therapy A patient s cost share for preferred tier specialty drugs on the formulary (drug list) should be $250 or less per month When coupons were applied, they reduced patient cost share to less than $250 and saved patients $6 of every $10 they are asked to pay out of pocket Unless used on preferred specialty drugs, coupons may undermine insurer s ability to manage costs, risking increases to premiums Laws banning specialty drug tiers will likely increase costs and limit access Prime Therapeutics LLC
37 Health Affairs thanks For its generous support of the October 2014 cluster of articles on Specialty Pharmaceuticals and this briefing.
38
39 What is 340B? Federal program intended to allow some hospitals that care for the poor to obtain drugs at reduced prices. Manufacturers must extend these discounts for drugs available to patients insured by Medicaid.
40
41 When the West Clinic merged with Methodist Hospital, Dr. Lee S. Schwartzberg, said the 340B program definitely was a factor in the decision to form the partnership. - NY Times, We investigate whether program expansions are consistent with program goal to serve the poor. Are newer 340B hospitals and newer affiliations capturing more poor patients or better insured ones?
42 Old and new 340B hospitals and their clinic affiliations
43 If nonprofit hospitals are essentially profiting from the 340B program without passing those savings to its patients, then the 340B program is not functioning as intended. -Senator Charles E. Grassley
44 A Conversation On Specialty Pharmaceuticals Troyen A. Brennan, MD, CVS Health Peter Bach, MD, Memorial Sloan Kettering s Center for Health Policy and Outcomes Alan Weil, Moderator
45 Health Affairs thanks For its generous support of the October 2014 cluster of articles on Specialty Pharmaceuticals and this briefing.
46 Thank You! Please be sure to join us for these upcoming events: November Issue Briefing: Communities and Health Wednesday, November 5, National Press Club December Briefing: Children s Health Monday, December 8, National Press Club
Formulary Management
Formulary Management Formulary management is an integrated patient care process which enables physicians, pharmacists and other health care professionals to work together to promote clinically sound, cost-effective
More informationArthritis Foundation Position Statement on Biosimilar Substitution
Arthritis Foundation Position Statement on Biosimilar Substitution The Affordable Care Act creates a regulatory pathway for the approval of a new generation of biologic medications called biosimilars.
More information2014 Prescription Drug Schedule Humana Medicare Employer Plan
2014 Prescription Drug Schedule Humana Medicare Employer Plan Option 98 City of Newport News Y0040_GHHHEF3HH14 SECTION I - INTRODUCTION TO SUMMARY OF BENEFITS Thank you for your interest in the Humana
More informationWhat Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the
More informationThe Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion
November 2013 Edition Vol. 7, Issue 10 The Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion By Gordon Gochenauer, Director, Oncology Commercial Strategies,
More informationRE: Essential Health Benefits: Follow Up from the October 2014 Patient Coalition Meeting
Mr. Kevin Counihan Marketplace Chief Executive Officer (CEO) Centers for Medicare & Medicaid Services 7501 Wisconsin Avenue Bethesda, MD 20814 November 18, 2014 RE: Essential Health Benefits: Follow Up
More informationOPTIMIZING SCIENTIFIC VALUE: SMART AND SYSTEMATIC APPROACHES TO MEDICAL PUBLICATIONS
OPTIMIZING SCIENTIFIC VALUE: SMART AND SYSTEMATIC APPROACHES TO MEDICAL PUBLICATIONS April 27 29, 2015 Hyatt Regency Crystal City Arlington, VA, USA 11TH ANNUAL MEETING OF ISMPP 1 ORGANIZED HEALTHCARE
More informationTRENDS SHAPING THE FUTURE OF PERSONALIZED CARE AND THE DELIVERY OF SPECIALTY PHARMACY
TRENDS SHAPING THE FUTURE OF PERSONALIZED CARE AND THE DELIVERY OF SPECIALTY PHARMACY Key Takeaways from the June 18, 2013 Regional Symposium Nashville, Tennessee THE SYMPOSIUM Trends Shaping the Future
More informationFebruary 19, 2016. RE: Gilead Report Responses. Dear Senators Wyden and Grassley:
February 19, 2016 The Honorable Ron Wyden The Honorable Chuck Grassley Committee on Finance United States Senate 219 Dirksen Senate Office Building Washington, DC 20510-6200 RE: Gilead Report Responses
More informationFEHB Program Carrier Letter All FEHB Carriers
FEHB Program Carrier Letter All FEHB Carriers U.S. Office of Personnel Management Healthcare and Insurance Letter No. 2016-03 Date: February 26, 2016 Fee-for-service [3] Experience-rated HMO [3] Community-rated
More informationHow To Understand And Understand Biosimilars
Welcome to Biosimilars 20/20, presented by the Specialty Pharma Education Center (SPEC) in partnership with the Specialty Pharma Journal (SPJ). Please note that this is a preliminary agenda that is subject
More informationS P E C I A L I S T A N D M A S T E R S T U D I E S
University Ss, Cyril and Methodius Skopje FACULTY OF PHARMACY S P E C I A L I S T A N D M A S T E R S T U D I E S Healthcare management and pharmacoeconomics Skopje, 2007 STUDY PLAN -Specialist Studies-
More information5/5/2015 PHARMACY WHAT S AN EMPLOYER TO DO? Current Structure Misaligned
PHARMACY WHAT S AN EMPLOYER TO DO? MAY 15, 2015 Debbie Doolittle Nashville, TN Pharmaceutical Spending Per Capita, 2013 vs. 2018 The US vs. the Rest of the World 1 Current Pharmacy Landscape How Did We
More informationAdapting Pharmaceutical Reimbursement Policies to Manage Spending on High-Cost Drugs
Adapting Pharmaceutical Reimbursement Policies to Manage Spending on High-Cost Drugs Elizabeth Docteur, Principal, Elizabeth Docteur Consulting Ruth Lopert, Deputy Director, Pharmaceutical Policy & Strategy
More informationObjectives. P&T Committee. P&T Committee Structure. Utilization of P&T Committees
Objectives Discuss overview of forum purpose. Drug Information used in the Managed Care Pharmacy P&T Decision Making Process: Current Practice and Insights Diana Brixner, RPh, PhD Professor and Chair,
More informationIntroduction. Plan sponsors include employers, unions, trust funds, associations and government agencies, and are also referred to as payors.
Maintaining the Affordability of the Prescription Drug Benefit: How Managed Care Organizations Secure Price Concessions from Pharmaceutical Manufacturers Introduction The purpose of this paper is to explain
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationHealth Insurance and Cancer Drug Reimbursement
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Health Insurance and Cancer Drug Reimbursement Michael Kolodziej, M.D., FACP National Medical Director, Oncology
More informationHow to Request an Exception or Appeal a Decision From Your Prescription Drug Plan
How to Request an Exception or Appeal a Decision From Your Prescription Drug Plan Exceptions What is an Exception? Sometimes you may not be able to obtain a prescription medication that your healthcare
More informationTHE AFFORDABLE CARE ACT: KEY POINTS FOR PHARMACISTS. Sarah M. Smith, Pharm.D., BCACP Douglas H. Kay Symposium June 11, 2014
THE AFFORDABLE CARE ACT: KEY POINTS FOR PHARMACISTS Sarah M. Smith, Pharm.D., BCACP Douglas H. Kay Symposium June 11, 2014 Objectives 1. Summarize the major changes the Affordable Care Act (ACA) will have
More informationAn Evaluation of Specialty Drug Pricing Under the Pharmacy and Medical Benefit
An Evaluation of Specialty Drug Pricing Under the Pharmacy and Medical Benefit March 2014 PREPARED BY Brenda Motheral, MBA, PhD President Corey Belken, PharmD Vice President Artemetrx Specialty Drug Solutions
More informationInsurance Exchanges: New Market Opportunities & Threats to Access. February 2014 avalerehealth.net
Insurance Exchanges: New Market Opportunities & Threats to Access February 2014 avalerehealth.net Despite Slow Initial Enrollment, Exchange Participation Is Accelerating Most Sign-Ups Expected Close to
More informationLICENSING COMMITTEE AD-HOC Committee on Pharmaceutical Benefit Managers (PBMs) Regulation. Meeting Summary
California State Board of Pharmacy STATE AND CONSUMER SERVICES AGENCY 400 R Street, Suite 4070, Sacramento, CA 95814-6237 DEPARTMENT OF CONSUMER AFFAIRS Phone (916) 445-5014 GRAY DAVIS, GOVERNOR Fax (916)
More informationNovember 4, 2010. Honorable Paul Ryan Ranking Member Committee on the Budget U.S. House of Representatives Washington, DC 20515.
CONGRESSIONAL BUDGET OFFICE U.S. Congress Washington, DC 20515 Douglas W. Elmendorf, Director November 4, 2010 Honorable Paul Ryan Ranking Member Committee on the Budget U.S. House of Representatives Washington,
More informationHealth Care Services
Abdulaziz H Al Saggabi, BSc, MSc, PharmD, Director, Drug Policy & Economics Center National Guard Health Affair & President ISPOR Saudi Arabia Chapter Presentation Outline y Background of Saudi Arabia
More informationRemaining Open Enrollment Meetings 900 Room, Monday, Oct. 26, 9:30-10:30 900 Room, Tuesday, Nov. 3, 3:00-4:00
Please Note: You must complete the open enrollment process online by Saturday, November 7 th. Not completing open enrollment will result in the loss of benefits in 2016. Our open enrollment process will
More informationUnderstanding Hepatitis C Treatment Access
Understanding Hepatitis C Treatment Access Robert Greenwald, JD, Clinical Professor of Law & Director, Center for Health Law and Policy Innovation of Harvard Law School May 2015 Comments Based on Findings
More informationPRINCIPAL DEPUTY ADMINISTRATOR, DEPUTY ADMINISTRATOR FOR INNOVATION AND QUALITY, AND CHIEF MEDICAL OFFICER, CENTERS FOR MEDICARE & MEDICAID SERVICES
STATEMENT OF PATRICK CONWAY, MD, MSc ACTING PRINCIPAL DEPUTY ADMINISTRATOR, DEPUTY ADMINISTRATOR FOR INNOVATION AND QUALITY, AND CHIEF MEDICAL OFFICER, CENTERS FOR MEDICARE & MEDICAID SERVICES ON EXAMINING
More informationThe Rising Tide of Pharmacy Benefit Cost and Complexity: A health plans roadmap to optimizing pharmacy services relationships
The Rising Tide of Pharmacy Benefit Cost and Complexity: A health plans roadmap to optimizing pharmacy services relationships New pharmacy benefit challenges After several years of manageable pharmacy
More informationFULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION NEW ENGLAND JOURNAL OF MEDICINE 2011; DOI: 10.
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION NEW ENGLAND JOURNAL OF MEDICINE 2011; DOI: 10.1056/NEJMSA1107913 Niteesh K. Choudhry, MD, PhD, 1 Jerry Avorn, MD, 1 Robert J. Glynn,
More informationPayer Mix in Oncology
Emerging Markets Market Access & Health Outcomes Oncology Payer Mix in Oncology Understanding cancer payer mix is critical to understanding patient affordability as a component of launch planning Digital
More informationHarvard Pilgrim s Stride SM. (HMO) Medicare Advantage Plan. Value Rx Plus Annual Notice of Change
HP15ANOCMNEPLUS 2015 Harvard Pilgrim s Stride SM (HMO) Medicare Advantage Plan Value Rx Plus Annual Notice of Change Maine Cumberland and York Y0098_15092 Accepted Harvard Pilgrim Stride Value RX Plus
More informationNatalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services. CVS Caremark Corporation
Prepared Statement of Natalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services CVS Caremark Corporation Before the Subcommittee on Regulatory Reform, Commercial and Antitrust
More informationDo No Harm: Congress Should Leave Canadian Prescription Drugs Alone
Submission by the Canadian Pharmacists Association, the Ontario Pharmacists Association, and the Best Medicines Coalition to the Subcommittee on Interstate Commerce, Trade and Tourism of the Senate Committee
More informationPrescription drug costs continue to rise at
Prescription Drugs Developing an Effective Generic Prescription Drug Program by John D. Jones Pharmacy benefit managers (PBMs) use a variety of pricing strategies. When employers have a thorough knowledge
More informationThe Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) exists to find cures and ensure access to treatments for blood cancer patients. LLS is the voice for all blood cancer patients. We
More informationIs it time for a new drug development paradigm?
Is it time for a new drug development paradigm? Robert McDonough, M.D. Senior Director, Clinical Policy Research and Development 1 The Aetna Way Our Cause To make quality health care more affordable and
More informationHealth Care Reform Legislation and You
(Customizable space for CPA Firm Logo to go here) Health Care Reform Legislation and You Timelines and Implications of the New Law for Individuals Updated as of January 2011 The Health Care Reform Legislation
More informationHCSP GUIDES A GUIDE TO: PREPARING FOR TREATMENT. A publication of the Hepatitis C Support Project
HCSP GUIDES T R E AT M E N T I S S U E S A publication of the Hepatitis C Support Project The information in this guide is designed to help you understand and manage HCV and is not intended as medical
More informationADAP and Insurance: Purchasing/Continuing Insurance and Utilizing Pharmacy Benefits Managers/Insurance Benefits Managers
ADAP and Insurance: Purchasing/Continuing Insurance and Utilizing Pharmacy Benefits Managers/Insurance Benefits Managers Amy Killelea and Britten Pund, NASTAD June 12, 2013 Agenda Overview of ADAPs ability
More informationBasic Reimbursement - Medicare Part D Specifics
Basic Reimbursement - Medicare Part D Specifics 60889-R8-V1 (c) 2012 Amgen Inc. All rights reserved 2 This information is provided for your background education and is not intended to serve as guidance
More informationPrescription Drug Pricing
Prescription Drug Pricing Anna Cook Julie Somers Julia Christensen Congressional Budget Office January 30, 2009 Manufacturers Shipments of Drugs Through the Supply Chain Key Prices in the Pharmaceutical
More informationExperience & Trends determines the District Insurance Rates. Claims are processed through our TPA and PBM = BCBSTX/Prime
Open Enrollment Meeting 2014-15 Plan Year Self-Funded Medical and Rx Plan Experience & Trends determines the District Insurance Rates Claims are processed through our TPA and PBM = BCBSTX/Prime AISD Contributions
More informationDeveloping payment policy to promote use of services based on clinical evidence. Nancy Ray, Lauren Metayer, John Richardson March 6, 2014
Developing payment policy to promote use of services based on clinical evidence Nancy Ray, Lauren Metayer, John Richardson March 6, 2014 Rethinking Medicare s quality strategy Focus Medicare s quality
More informationUniversity of Nebraska Prescription Drug Program 2014
University of Nebraska Prescription Drug Program 2014 The University of Nebraska s prescription benefit program is administered by CVS Caremark, a leading national provider of prescription drug benefit
More informationHealth Care Reform Legislation and You
Health Care Reform Legislation and You Timelines and Implications of the New Law for Individuals Updated as of May 2011 Health Care Reform Legislation and You The Patient Protection and Affordable Care
More informationTargeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute
Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia New England Healthcare Institute NEHI Innovation Series March 2004 Executive Summary From drugs and medical devices, to information
More informationHEALTHCARE REFORM SOLUTIONS. Designing a Pharmacy Benefit for the New Public Health Exchange Consumers
HEALTHCARE REFORM SOLUTIONS Designing a Pharmacy Benefit for the New Public Health Exchange Consumers FEBRUARY 2013 EXECUTIVE SUMMARY Designing a Pharmacy Benefit for the New Public Health Insurance Exchange
More informationThe alignment of clinical and financial. Applying Value-Based Insurance Design To Low-Value Health Services. Value-Based Insurance Design
By A. Mark Fendrick, Dean G. Smith, and Michael E. Chernew Applying Value-Based Insurance Design To Low-Value Health Services doi: 10.1377/hlthaff.2010.0878 HEALTH AFFAIRS 29, NO. 11 (2010): 2017 2021
More informationfocus Retiree Open Enrollment What s New for You in FY17? Open Enrollment is May 11 th to May 25 th Open Enrollment Information Meetings
Retiree Open Enrollment focus What s New for You in FY17? It s here again! This May s Open Enrollment is the opportunity for pre-medicare retirees and Medicare retirees to make insurance changes. Any change
More informationSpecialty Pharmacy? Disclosure. Objectives Technician
Disclosure What s so SPECIAL about? I have no actual or potential conflict of interest in relation to this program/presentation. Michael DeCoske, PharmD, BCPS Associate Chief Pharmacy Officer Duke University
More informationStrategic Issues in Managing the Specialty Pharmacy Benefit. Tim Watson, PharmD, MBA
Strategic Issues in Managing the Specialty Pharmacy Benefit Tim Watson, PharmD, MBA Strategic Issues in Specialty Pharmacy Management Specialty pharmacy goals: Provide a reliable source for hard-to-find
More informationEMEA RM DRAFT GUIDANCE ISPE RESPONSE 1
EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1 October 4, 2005 Guideline on Risk Management Systems for Medicinal Products for Human Use DRAFT London, 6 September 2005. This guideline will be included as chapter
More informationMEDICARE PART D PRESCRIPTION DRUG COVERAGE 2016
PO Box 350 Willimantic, Connecticut 06226 (860)456-7790 (800)262-4414 1025 Connecticut Ave, NW Suite 709 Washington, DC 20036 (202)293-5760 MEDICARE PART D PRESCRIPTION DRUG COVERAGE 2016 Se habla español
More informationMarket Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform
Market Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform By Joakim Steen Mikkelsen, Managing Healthcare Counselor, Embassy of
More informationFULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES Niteesh K. Choudhry, MD, PhD Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics
More informationBancorp Insurance Medicare Vocabulary
Bancorp Insurance Medicare Vocabulary Advance Beneficiary Notice (ABN) A notice indicating the cost of a service that Medicare might not cover. Accepting Assignment Your Doctor agrees to accept payment
More informationEnclosed is information to help guide you through the Part D appeals process.
Date: Dear Helpline Caller: The Medicare Rights Center is a national, nonprofit organization. We help older adults and people with disabilities with their Medicare problems. We support caregivers and train
More informationPfizer Struggles to Maintain Lipitor Sales Will Aggressive Discounting and Rebating Pay Off?
Pfizer Struggles to Maintain Lipitor Sales Will Aggressive Discounting and Rebating Pay Off? Research February 6, 2012 Rusty Jones Companies: Pfizer (PFE) Ranbaxy (OTC: RBXZF) Watson (WPI) Products: Lipitor
More informationAetna Savings Plus plan guide
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Aetna Savings Plus plan guide New health plans designed with Florida businesses in mind For businesses with 2-100
More informationCLOSING THE COVERAGE GAP. Pan-Canadian Pharmacare
CLOSING THE COVERAGE GAP Pan-Canadian Pharmacare Prescription drug coverage for all Canadians While the vast majority of Canadians have access to prescription drugs, some Canadians can t afford their medications.
More informationHEALTH POLICY AFFORDABLE CARE ACT AND STATE MEDICAID CHANGES. NEW Members Conference of the Illinois General Assembly November 27-28, 2012
HEALTH POLICY AFFORDABLE CARE ACT AND STATE MEDICAID CHANGES NEW Members Conference of the Illinois General Assembly November 27-28, 2012 Robert Kaestner, PhD Institute of Government and Public Affairs,
More information2012 Summary of Benefits
2012 Summary of Benefits 1 / Value Orange Drug Plan North Carolina Benefits effective January 1, 2012 S5678 Health Net Life Insurance Company Material ID# S5678_2012_0058 CMS Approved 08152011 SECTION
More informationUse of Social Media by Pharmaceutical Medical Information Teams
www.arisglobal.com A White Paper Presented By ArisGlobal Use of Social Media by Pharmaceutical Medical Information Teams Ome Ogbru, PharmD, Medical Information SME What is Social Media? The Merriam-Webster
More informationPrescription Drugs. Inside this Brief. Background Brief on. Spending for Prescription Drugs. Medicare and. Prescription Drugs. State Discount Programs
Background Brief on September 2014 Inside this Brief Spending for Prescription Drugs Medicare and Prescription Drugs State Discount Programs Discount Cards and Assistance Programs Oregon Prescription Drug
More informationAugust 7, 2014. Dear Mr. Helgerson:
August 7, 2014 Chain Pharmacy Association of New York State New York Chapter, American Society of Consultant Pharmacists New York State Council of Health System Pharmacists Pharmacists Society of the State
More informationThe fourth hurdle system. International HTA agencies. Australian PBAC. Difference between health technology regulatory body and HTA body
* This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Local Application
More informationMedicare Part D Prescription Drug Coverage
Medicare Part D Prescription Drug Coverage Part 3 Version 7.1 August 1, 2013 Terms and Conditions This training program is protected under United States Copyright laws, 17 U.S.C.A. 101, et seq. and international
More informationSummary of the Major Provisions in the Patient Protection and Affordable Health Care Act
Summary of the Major Provisions in the Patient Protection and Affordable Care Act Updated 10/22/10 On March 23, 2010, President Barack Obama signed into law comprehensive health care reform legislation,
More informationE. Christopher Ellison, MD, F.A.C.S Senior Associate Vice President for Health Sciences
Accountable Care Organizations and You E. Christopher Ellison, MD, F.A.C.S Senior Associate Vice President for Health Sciences CEO, OSU Faculty Group Practice Chair, Department of Surgery Ohio State University
More informationThe Basics of Pharmacy Benefits Management (PBM) 2009
The Basics of Pharmacy Benefits Management (PBM) 2009 Andrew Kingery Pharmacy Account Management Virginia CE Forum 2009 Course# 201719 Objectives & Introduction Provide basic components of a PBM Define
More informationJ Clin Oncol 28:3234-3238. 2010 by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 20 JULY 10 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support
More informationCHOOSING A PURDUE RETIREE. Health Care Plan. That s Right for You
CHOOSING A PURDUE RETIREE Health Care Plan That s Right for You Agenda 2016 Health Care Options Medicare Advantage PPO Prescription Drug Benefits PURcare Prescription Drug Benefits Other benefits Future
More informationEvaluating the impact of REMS on burden and patient access
Evaluating the impact of REMS on burden and patient access Doris Auth, Pharm.D. Team Leader, Division of Risk Management Office of Medication Error Prevention and Risk Management Center for Drug Evaluation
More informationPHARMACY BENEFIT DESIGN CONSIDERATIONS
PHARMACY BENEFIT DESIGN CONSIDERATIONS Is your pharmacy benefit designed for your employees or the big drug companies? The pharmacy (or prescription) benefit is one of the most sought after benefits by
More informationGuide to the Summary and Benefits of Coverage
Guide to the Summary and Benefits of Coverage The Affordable Care Act (ACA) makes health insurance available to nearly all Americans. Each state has a health insurance marketplace, also known as a health
More informationCan an administrative drug claims database be used to understand claimant drug utilization?
Can an administrative drug claims database be used to understand claimant drug utilization? By Elaine McKenzie, BSP, MBA, Consultant, TELUS Health Analytics Elaine McKenzie is a consultant who works with
More informationMedicare Part D Prescription Drug Coverage
Medicare Part D Prescription Drug Coverage Part 3 Version 9.0 June 22, 2015 Terms and Conditions This training program is protected under United States Copyright laws, 17 U.S.C.A. 101, et seq. and international
More informationSubmitted electronically to http://www.regulations.gov
Submitted electronically to http://www.regulations.gov Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMS-3288-NC P.O. Box 8016 Baltimore, MD 21244-8016 RE:
More informationChoosing the Best Plan for You: A Tool for Purchasing Coverage in the Health Insurance Exchange
Choosing the Best Plan for You: A Tool for Purchasing Coverage in the Health Insurance Exchange The Affordable Care Act (ACA) makes health insurance available to nearly all Americans and the law requires
More informationIncreasing Health Care Costs and Your Employee Health Plan
Exhibit 1 PERSPECTIVES PROVIDING INSIGHT INTO TODAY'S EMPLOYEE BENEFITS ISSUES Increasing Health Care Costs and Your Employee Health Plan Eleventh Edition A Annual Health Care Cost Increases, National
More informationDecember 5, 2006. Reference File Code: CMS-4119-P. Dear Sir or Madam:
Page 1 of 5 1101 Pennsylvania Avenue Suite 600 Washington, DC 20004-2514 202.756.2227 202.756.7506 [fax] www.accp.com Department of Government & Professional Affairs December 5, 2006 Centers for Medicare
More informationClinical Trials: The Crux of Cancer Innovation
Clinical Trials: The Crux of Cancer Innovation Even as medical science is transforming cancer care, major deficiencies in the way cancer clinical trials are designed, carried out, regulated and funded
More informationTracking Employment-Based Health Benefits in Changing Times
Tracking Employment-Based Health Benefits in Changing Times by Brian Mauersberger Bureau of Labor Statistics Originally Posted: January 27, 2012 Most Americans obtain their health care coverage through
More informationInstitute for Safe Medication Practices
Institute for Safe Medication Practices 1800 Byberry Road, Suite 810 Huntingdon Valley, PA 19006 FOR MORE INFORMATION, CONTACT : Michael A. Donio, MPA Marketing & Consumer Affairs 215-947-7797 Mdonio@ismp.org
More informationUNDERSTANDING THE CONTENT OUTLINE/CLASSIFICATION SYSTEM
BOARD OF PHARMACY SPECIALTIES PHARMACOTHERAPY SPECIALIST CERTIFICATION CONTENT OUTLINE/CLASSIFICATION SYSTEM FINALIZED SEPTEMBER 2015/FOR USE ON FALL 2016 EXAMINATION AND FORWARD UNDERSTANDING THE CONTENT
More informationSTATE POLICY ADVOCACY PRIORITIES. American Academy of Dermatology Association
STATE POLICY ADVOCACY PRIORITIES American Academy of Dermatology Association Access to Pharmaceuticals/Cost Transparency AADA collaborates with manufacturers, the health care community, policymakers, private
More informationPACIFIC ISLANDERS AND HEALTH CARE REFORM: ACCESS AND COVERAGE FEBRUARY 14/15, 2011
PACIFIC ISLANDERS AND HEALTH CARE REFORM: ACCESS AND COVERAGE FEBRUARY 14/15, 2011 Welcome Dr. Garth Graham Deputy Assistant Secretary Office of Minority Health Herb Schultz Region IX Director James Mason
More informationBrandeis University The Heller School for Social Policy and Management
Health Care Cost Management in Massachusetts: A Discussion of Options Meeting #3: Boston, MA Conference Report Sponsored by: Health Care Cost Containment and Value-Based Insurance Design Presenter: Michael
More informationPrescription drugs are a critical component of health care. Because of the role of drugs in treating conditions, it is important that Medicare ensures that its beneficiaries have access to appropriate
More information2015 Regence Medicare Prescription Drug Plans (PDP)
VIEW PLA OVER DECISION GUIDE 2015 Regence Medicare Prescription Drug Plans (PDP) Regence BlueShield of Idaho and Regence BlueCross BlueShield of Utah is an Independent Licensee of the Blue Cross and Blue
More informationIowa Wellness Plan 1115 Waiver Application Final
11.1 Summary of Public Comment Iowa Wellness Plan 1115 Waiver Application Final The majority of the comments were generally supportive of the consensus reached to create two Iowa waiver proposals and expand
More informationTHAT S RIGHT FOR YOU PLATINUM BLUESM WITH RX (COST) Medical and prescription drug benefits you want. Value you deserve. FIND THE PLAN CORE CHOICE
2016 PLATINUM BLUESM WITH RX (COST) Medical and prescription drug benefits you want. Value you deserve. OPTIONS YOU WANT Platinum Blue can help pay the deductibles, copayments and coinsurance Original
More informationUHC Branded Specialty Pharmacy Program
UHC Branded Specialty Pharmacy Program Evolution to Implementation Jake Groenewold, Senior Vice President, UHC Doug Smith, PharmD, Senior Director, UHC Kevin Colgan, MA, FASHP, Corporate Director of Pharmacy,
More informationPrivacy Space. Public Place. How to Protect PHI and be HIPAA Compliant
Privacy Space. Public Place. How to Protect PHI and be HIPAA Compliant Event Type Live Online ACPE Expiration Date 12/11/2016 Credits 1 Contact Hour Target Audience Pharmacy Technicians Program Overview
More informationPRESCRIPTION MEDICINES: COSTS IN CONTEXT
PRESCRIPTION MEDICINES: COSTS IN CONTEXT 2015 Since 2000, biopharmaceutical companies have brought MORE THAN 500 NEW TREATMENTS AND CURES to U.S. patients In the last 100 years, medicines have helped raise
More informationThe Factors Fueling Rising Health Care Costs 2008
The Factors Fueling Rising Health Care Costs 2008 Prepared for America s Health Insurance Plans, December 2008 2008 America s Health Insurance Plans Table of Contents Executive Summary.............................................................2
More informationHealth Care Expenditures. Definitions: GNP vs. GDP. More terms: CPI, PPI, MPI
Health Care Expenditures Objectives 1.Understand the definition and purpose of the gross national product (GNP), gross domestic product (GDP), consumer price index (CPI), and producer price index (PPI).
More informationPHARMACEUTICAL MANAGEMENT PROCEDURES
PHARMACEUTICAL MANAGEMENT PROCEDURES THE FORMULARY The purpose of Coventry Health Care s formulary is to encourage use of the most cost-effective drugs. The formulary is necessary because the cost of prescription
More information